BACKGROUND: Several animal models for xenogenic (xeno) graft versus host disease (GVHD) have been developed in immunodeficient mice, such as C.B-17-scid and nonobese diabetes (NOD)/severe combined immunodeficiency (SCID), by human peripheral blood mononuclear cell (hPBMC) transplantation. However, these models pose problems because they require sublethal total body irradiation of the mice and a large number of hPBMCs to induce GVHD, and the timing of onset of GVHD is also unstable. The aim of this study is to establish improved murine models of xeno-GVHD using novel immunodeficient NOD/Shi-scid IL2r gamma null (NOG) mice. METHODS: In three strains of immunodeficient mice, NOG, BALB/cA-RAG2 IL2r gamma null, and NOD/SCID mice, GVHD was induced by transplantation of hPBMCs with or without total body irradiation, and the GVHD symptoms in these strains were compared. RESULTS: After intravenous transplantation of hPBMCs, NOG mice showed early onset of GVHD symptoms and a small number of hPBMCs (2.5 x 10(6)) was sufficient to induce GVHD when compared with BALB/cA-RAG2 null IL2r gamma null and NOD/SCID mice. In addition, total body irradiation was not always necessary in the present model. CONCLUSIONS: These results indicate that our model using the NOG mouse is a useful tool to investigate GVHD and to develop effective drugs for GVHD.
BACKGROUND: Several animal models for xenogenic (xeno) graft versus host disease (GVHD) have been developed in immunodeficientmice, such as C.B-17-scid and nonobese diabetes (NOD)/severe combined immunodeficiency (SCID), by human peripheral blood mononuclear cell (hPBMC) transplantation. However, these models pose problems because they require sublethal total body irradiation of the mice and a large number of hPBMCs to induce GVHD, and the timing of onset of GVHD is also unstable. The aim of this study is to establish improved murine models of xeno-GVHD using novel immunodeficient NOD/Shi-scidIL2r gamma null (NOG) mice. METHODS: In three strains of immunodeficientmice, NOG, BALB/cA-RAG2IL2r gamma null, and NOD/SCIDmice, GVHD was induced by transplantation of hPBMCs with or without total body irradiation, and the GVHD symptoms in these strains were compared. RESULTS: After intravenous transplantation of hPBMCs, NOG mice showed early onset of GVHD symptoms and a small number of hPBMCs (2.5 x 10(6)) was sufficient to induce GVHD when compared with BALB/cA-RAG2 null IL2r gamma null and NOD/SCIDmice. In addition, total body irradiation was not always necessary in the present model. CONCLUSIONS: These results indicate that our model using the NOG mouse is a useful tool to investigate GVHD and to develop effective drugs for GVHD.
Authors: G Blank; C Welker; J Haarer; M Sterk; S Nadalin; V A C Yañez; T O Joos; A Menrad; D Snell; G LaCorcia; A Königsrainer; R Handgretinger; K Schilbach Journal: Bone Marrow Transplant Date: 2014-11-17 Impact factor: 5.483
Authors: Danieli Andrade; Patricia B Redecha; Milena Vukelic; Xiaoping Qing; Giorgio Perino; Jane E Salmon; Gloria C Koo Journal: Arthritis Rheum Date: 2011-09
Authors: Leonard D Shultz; James Keck; Lisa Burzenski; Sonal Jangalwe; Shantashri Vaidya; Dale L Greiner; Michael A Brehm Journal: Mamm Genome Date: 2019-03-07 Impact factor: 2.957
Authors: Ling Lu; Qin Lan; Zhiyuan Li; Xiaohui Zhou; Jian Gu; Qiang Li; Julie Wang; Maogen Chen; Ya Liu; Yi Shen; David D Brand; Bernhard Ryffel; David A Horwitz; Francisco P Quismorio; Zhongmin Liu; Bin Li; Nancy J Olsen; Song Guo Zheng Journal: Proc Natl Acad Sci U S A Date: 2014-08-06 Impact factor: 11.205